Zobrazeno 1 - 10 of 40 pro vyhledávání: '"Block MH"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Transcriptome-Derived Amplicon Sequencing Markers Elucidate the U.S. Podosphaera macularis Population Structure Across Feral and Commercial Plantings of Humulus lupulus .
Autor: Weldon WA; Section of Plant Pathology and Plant-Microbe Biology, Cornell AgriTech, Cornell University, Geneva, NY 14456., Knaus BJ; Department of Botany and Plant Pathology, Corvallis, OR 97331., Grünwald NJ; U.S. Department of Agriculture-Agricultural Research Service Horticultural Crops Research Unit, Corvallis, OR 97330., Havill JS; Department of Agronomy and Plant Genetics, University of Minnesota, St. Paul, MN 55108., Block MH; Department of Botany and Plant Pathology, Corvallis, OR 97331., Gent DH; U.S. Department of Agriculture-Agricultural Research Service Forage Seed and Cereal Research Unit, Corvallis, OR 97331., Cadle-Davidson LE; Section of Plant Pathology and Plant-Microbe Biology, Cornell AgriTech, Cornell University, Geneva, NY 14456.; U.S. Department of Agriculture-Agricultural Research Service Grape Genetics Research Unit, Geneva, NY 14456., Gadoury DM; Section of Plant Pathology and Plant-Microbe Biology, Cornell AgriTech, Cornell University, Geneva, NY 14456.
Publikováno v: Phytopathology [Phytopathology] 2021 Jan; Vol. 111 (1), pp. 194-203. Date of Electronic Publication: 2020 Dec 01.
Zobrazit plný text záznamu
6
Akademický článek
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Autor: Gingipalli L; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA. Electronic address: lakshmaiah.gingipalli@astrazeneca.com., Block MH; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Bao L; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Cooke E; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Dakin LA; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Denz CR; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Ferguson AD; Structure and Biophysics, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Johannes JW; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Larsen NA; Structure and Biophysics, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Lyne PD; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Pontz TW; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Wang T; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Wu X; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Wu A; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Zhang HJ; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Zheng X; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Dowling JE; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA., Lamb ML; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2018 May 01; Vol. 28 (8), pp. 1336-1341. Date of Electronic Publication: 2018 Mar 07.
Zobrazit plný text záznamu
7
Akademický článek
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.
Autor: Yang B; Oncology Innovative Medicine Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Lamb ML, Zhang T, Hennessy EJ, Grewal G, Sha L, Zambrowski M, Block MH, Dowling JE, Su N, Wu J, Deegan T, Mikule K, Wang W, Kaspera R, Chuaqui C, Chen H
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2014 Dec 11; Vol. 57 (23), pp. 9958-70. Date of Electronic Publication: 2014 Dec 02.
Zobrazit plný text záznamu
8
Akademický článek
Structure-based design and synthesis of tricyclic IAP (Inhibitors of Apoptosis Proteins) inhibitors.
Autor: Hird AW; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States. Electronic address: alexander.hird@astrazeneca.com., Aquila BM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Block MH; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Hennessy EJ; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Kamhi VM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Omer CA; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Laing NM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Saeh JC; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Sha L; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Yang B; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States.
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2014 Apr 01; Vol. 24 (7), pp. 1820-4. Date of Electronic Publication: 2014 Feb 24.
Zobrazit plný text záznamu
9
Akademický článek
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
Autor: Dowling JE; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Alimzhanov M; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Bao L; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Block MH; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Chuaqui C; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Cooke EL; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Denz CR; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Hird A; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Huang S; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Larsen NA; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Peng B; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Pontz TW; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Rivard-Costa C; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Saeh JC; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Thakur K; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ye Q; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zhang T; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Lyne PD; AstraZeneca , Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2013 Jul 03; Vol. 4 (8), pp. 800-5. Date of Electronic Publication: 2013 Jul 03 (Print Publication: 2013).
Zobrazit plný text záznamu
10
Akademický článek
Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors.
Autor: Wang T; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Lamb ML; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Block MH; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Davies AM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Han Y; Array BioPharma Inc. , 3200 Walnut Street, Boulder, Colorado 80301, United States., Hoffmann E; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ioannidis S; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Josey JA; Array BioPharma Inc. , 3200 Walnut Street, Boulder, Colorado 80301, United States., Liu ZY; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Lyne PD; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., MacIntyre T; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Mohr PJ; Array BioPharma Inc. , 3200 Walnut Street, Boulder, Colorado 80301, United States., Omer CA; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Sjögren T; Discovery Sciences, Innovative Medicines, AstraZeneca , Pepparedsleden S431 83 Mölndal, Sweden., Thress K; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Wang B; Array BioPharma Inc. , 3200 Walnut Street, Boulder, Colorado 80301, United States., Wang H; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Yu D; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zhang HJ; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2012 Jul 26; Vol. 3 (9), pp. 705-9. Date of Electronic Publication: 2012 Jul 26 (Print Publication: 2012).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje